Federal agency priorities under the Biden Administration

Start adding items to your reading lists:
Save this item to:
This item has been saved to your reading list.

To listen to all PwC Next in Health podcasts, click here. Subscribe and listen to all episodes at your convenience via any device at Apple Podcasts, Spotify and Stitcher.


Tune into this episode of PwC's Next in Health to hear Health Research Institute (HRI) leader, Benjamin Isgur, and HRI Regulatory Center leader, Trine Tsouderos in discussion with HRI's Erin McCallister on what pharma might expect from federal agencies, including:

  • Food and Drug Administration (FDA)'s potential to broaden / standardized policies implemented in response to the pandemic (i.e., clinical trial diversity, supply chain visibility)
  • How politics has impacted FDA productivity
  • Centers for Medicare & Medicaid Services (CMS)' approach to control drug spending
  • Health and Human Services' role in 340B changes

Topics: Federal agency policies, clinical trials, medical supply chain, controlled drug spending

Contact us

Benjamin Isgur

Benjamin Isgur

Health Research Institute Leader, PwC US

Trine K. Tsouderos

Trine K. Tsouderos

HRI Regulatory Center Leader, PwC US

Tel: +1 (312) 241 3824

Follow us